July 29 | 2021

2cureX appoints two internationally highly recognized oncologists as Clinical Advisors

Read more
July 19 | 2021

2cureX receives important ISO 13485:2016 certification

Read more
July 1 | 2021

2cureX and University Hospital of Hamburg-Eppendorf present IndiTreat data at ESMO GI for early-stage Pancreatic Cancer

Read more
June 22 | 2021

2cureX appoints 2 new VPs for its Commercial Operations

Read more
June 7 | 2021

ASCO Update – New Treatment strategy prolongs progression free survival in colorectal cancer patients

Read more
June 4 | 2021

REDEYE releases an updated 2cureX Equity Research Report

Read more
June 1 | 2021

Management exercise all warrants within the framework of the 2018 incentive program

Read more
May 27 | 2021

2cureX offentliggör delårsrapport för det första kvartalet 2021

Read more
May 27 | 2021

2cureX publishes interim report for the first quarter of 2021

Read more
May 27 | 2021

Communiqué from the Annual General Meeting of 2cureX AB

Read more
May 27 | 2021

Kommuniké från årsstämma i 2cureX AB

Read more
May 20 | 2021

2cureX’s clinical partner, University Hospital Vejle, presents positive results of the IndiTreat®-guided clinical trial in third line metastatic colorectal cancer at the ASCO 2021 Annual Meeting

Read more
May 11 | 2021

Teckningsoptioner av serie TO1 tecknades till cirka 96,75 procent och 2cureX AB tillförs cirka 31,40 MSEK

Read more
May 11 | 2021

Warrants of series TO1 were subscribed to approximately 96.75 percent and 2cureX AB receives approximately SEK 31.40 million.

Read more
May 6 | 2021

Mangold Fondkommission AB published an Analyst Report on 2cureX

Read more
May 6 | 2021

2cureX publishes the annual report for the fiscal year 2020

Read more
May 6 | 2021

2cureX offentliggör årsredovisning för räkenskapsåret 2020

Read more